Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Hoffmann-La Roche
Rutgers, The State University of New Jersey
Hoffmann-La Roche
Hoffmann-La Roche
University of Pittsburgh
Genentech, Inc.
National Cancer Institute (NCI)
Hoffmann-La Roche
Exelixis
Exelixis
Dana-Farber Cancer Institute
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Washington University School of Medicine
NeoImmuneTech
National Cancer Institute (NCI)
National Cancer Institute (NCI)
G1 Therapeutics, Inc.
Hoffmann-La Roche
Hoffmann-La Roche
SCRI Development Innovations, LLC
Affimed GmbH
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Medical College of Wisconsin
Grupo Espanol de Tumores Neuroendocrinos
Medical College of Wisconsin
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Hoffmann-La Roche
Hoffmann-La Roche
Bayer
Hoffmann-La Roche
Dana-Farber Cancer Institute
Fundación GECP
Indiana University